High-resolution Genetic Mapping of Maternal Effects and Epistatic Suppressors of Congenital Heart Disease Risk
先天性心脏病风险的母体效应和上位抑制因子的高分辨率基因图谱
基本信息
- 批准号:9256806
- 负责人:
- 金额:$ 3.07万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-02-01 至 2020-07-31
- 项目状态:已结题
- 来源:
- 关键词:AdultAgeAgingAneuploidyAnimal ModelBioinformaticsBiological ModelsCandidate Disease GeneCardiacChildChromosome MappingClinicalDatabasesEnvironmentExerciseFamilyGene-ModifiedGeneral PopulationGenerationsGenesGeneticGenetic PolymorphismGenetic VariationHeart AbnormalitiesHumanInbred StrainIncidenceIndividualInterventionLaboratoriesLinear ModelsLongevityMapsMaternal AgeMethodsModelingMolecularMorbidity - disease rateMothersMusMutateMutationNewborn InfantOperative Surgical ProceduresPathogenesisPlaguePopulationPreventionProcessQuantitative GeneticsResearch Project GrantsResolutionRiskRoleTestingTherapeuticTranslatingWorkage effectcongenital anomalycongenital heart disorderdisorder preventiondisorder riskeggexperienceexperimental studygenetic manipulationgenetic variantmortalitymouse modelnoveloffspringpediatric patientsreproductivesuccesstherapeutic targettraittranscription factor
项目摘要
PROJECT SUMMARY / ABSTRACT
Congenital heart disease (CHD) is the most common congenital anomaly, which leads to significant
morbidity and mortality in newborns. Although great surgical advances have reduced CHD mortality in newborns
and children, these patients are not cured. Many of these children grow up and experience serious morbidity and
truncated lifespans as adults. It has become evident that we need strategies to move our efforts away from
intervention and toward prevention. The first step in this endeavor is to understand the causes of CHD.
Surprisingly, environment and mutations are estimated to explain less than one-third of CHD cases. In many
cases, however, even when a vital cardiac gene is mutated, a heart defect does not occur. This highlights the
critical role that genetic modifiers have in CHD pathogenesis. Attempts to identify these modifier genes have had
marginal success in humans. This motivated us to look toward animal models, in which we can control the effects
of environment and genetics.
Our mouse model replicates CHD risk in susceptible people through a heterozygous mutation in Nkx2-5,
an essential cardiac transcription factor. We then use inbred strain crosses and quantitative genetic methods to
identify genetic polymorphisms that modify CHD risk in Nkx2-5+/- mice. Through this model system, we
inadvertently confirmed observations in humans that the offspring of older mothers have an elevated risk for CHD
even after ruling out aneuploidy. We also determined that this risk is due to factors within old mothers, not old
eggs. Remarkably, voluntary exercise for the aging mother is sufficient to reduce CHD risk to baseline levels.
Subsequent studies demonstrated that the magnitude of the maternal aging risk varied according to the genetic
background of our mice. This indicates that the age risk is a quantitative trait that regulates maternal factors,
which can either inflate or suppress the risk of CHD. In separate experiments focused on risk modifiers within
susceptible individuals, I discovered genetic loci that act as epistatic suppressors of CHD risk in multiple mouse
populations. If we were able to identify the genes responsible and mimic the effects of maternal exercise or
protective genetic loci, we could translate these benefits to the general population. Our past experiments were not
designed to detect individual genes. So instead of speculating about the genes responsible for the maternal age-
associated risk and epistatic suppression of CHD, we have chosen a prudent and unbiased approach to identify
these genes. We have partnered with the laboratory of James Cheverud to use a high-resolution, advanced
intercross mapping population to identify CHD modifier loci to nearly single-gene resolution. This study will be
the first to map novel genes and variants that modify CHD risk at high-resolution, and these results will serve as
a springboard for future research into congenital heart disease prevention.
We propose these specific aims:
AIM 1: Identify high-resolution genetic loci that modify the maternal age-associated risk of CHD.
AIM 2: Map high-resolution genetic loci and detect epistatic suppressors of CHD risk in the offspring.
项目总结/摘要
先天性心脏病(CHD)是最常见的先天性异常,其导致显著的
新生儿的发病率和死亡率。尽管外科手术的巨大进步降低了新生儿CHD的死亡率,
和儿童,这些病人是无法治愈的。这些儿童中的许多人长大后患上了严重的疾病,
缩短了成年人的寿命显然,我们需要战略,
干预和预防。这一奋进的第一步是了解CHD的原因。
令人惊讶的是,环境和突变估计只能解释不到三分之一的CHD病例。在许多
然而,在某些情况下,即使重要的心脏基因发生突变,也不会发生心脏缺陷。这凸显
遗传修饰剂在CHD发病机制中的关键作用。试图识别这些修饰基因的努力已经取得了进展。
在人类身上取得了微小的成功。这促使我们转向动物模型,在那里我们可以控制效果
环境和遗传学。
我们的小鼠模型通过Nkx 2 -5的杂合突变在易感人群中复制CHD风险,
一种重要的心脏转录因子然后,我们使用近交系杂交和数量遗传学方法,
在Nkx 2 -5+/-小鼠中鉴定改变CHD风险的遗传多态性。通过这个模型系统,我们
无意中证实了在人类中的观察,即高龄母亲的后代患冠心病的风险增加
即使排除了非整倍体我们还确定,这种风险是由于高龄母亲的因素,而不是年龄
鸡蛋值得注意的是,老年母亲的自愿运动足以将CHD风险降低到基线水平。
随后的研究表明,母亲衰老风险的大小因遗传因素而异。
我们老鼠的背景这表明,年龄风险是一个数量性状,调节母亲的因素,
它可以增加或抑制冠心病的风险。在单独的实验中,
在易感个体中,我发现了在多个小鼠中作为CHD风险上位抑制因子的遗传位点,
人口。如果我们能够识别出负责的基因,并模仿母亲锻炼的效果,
保护性基因位点,我们可以将这些好处转化为普通人群。我们过去的实验
用来检测单个基因所以与其去推测是哪些基因决定了母亲的年龄-
相关的风险和上位抑制冠心病,我们选择了一个谨慎和公正的方法,以确定
这些基因。我们与James Cheverud的实验室合作,
交叉绘图群体以几乎单基因分辨率识别CHD修饰基因座。本研究将
第一个以高分辨率绘制改变CHD风险的新基因和变体,这些结果将作为
为将来研究先天性心脏病的预防提供了一个跳板。
我们提出这些具体目标:
目的1:确定高分辨率的基因位点,修改母亲的年龄相关的冠心病的风险。
目的2:定位高分辨率遗传位点,检测后代CHD风险的上位性抑制因子。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ehiole Ogboma Akhirome其他文献
Ehiole Ogboma Akhirome的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ehiole Ogboma Akhirome', 18)}}的其他基金
High-resolution Genetic Mapping of Maternal Effects and Epistatic Suppressors of Congenital Heart Disease Risk
先天性心脏病风险的母体效应和上位抑制因子的高分辨率基因图谱
- 批准号:
9424419 - 财政年份:2017
- 资助金额:
$ 3.07万 - 项目类别:
相似国自然基金
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
- 批准号:JCZRQN202500010
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
- 批准号:2025JJ70209
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
- 批准号:
- 批准年份:2024
- 资助金额:0 万元
- 项目类别:面上项目
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
- 批准号:2023JJ50274
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
- 批准号:
- 批准年份:2022
- 资助金额:33 万元
- 项目类别:地区科学基金项目
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
- 批准号:n/a
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
- 批准号:81973577
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
- 批准号:81602908
- 批准年份:2016
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
高血糖激活滑膜AGE-RAGE-PKC轴致骨关节炎易感的机制研究
- 批准号:81501928
- 批准年份:2015
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
相似海外基金
The Phenomenon of Stem Cell Aging according to Methylation Estimates of Age After Hematopoietic Stem Cell Transplantation
根据造血干细胞移植后甲基化年龄估算干细胞衰老现象
- 批准号:
23K07844 - 财政年份:2023
- 资助金额:
$ 3.07万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Analysis of Age-dependent Functional Changes in Skeletal Muscle CB1 Receptors by an in Vitro Model of Aging-related Muscle Atrophy
通过衰老相关性肌肉萎缩的体外模型分析骨骼肌 CB1 受体的年龄依赖性功能变化
- 批准号:
22KJ2960 - 财政年份:2023
- 资助金额:
$ 3.07万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Joint U.S.-Japan Measures for Aging and Dementia Derived from the Prevention of Age-Related and Noise-induced Hearing Loss
美日针对预防与年龄相关和噪声引起的听力损失而导致的老龄化和痴呆症联合措施
- 批准号:
23KK0156 - 财政年份:2023
- 资助金额:
$ 3.07万 - 项目类别:
Fund for the Promotion of Joint International Research (International Collaborative Research)
The Effects of Muscle Fatigability on Gait Instability in Aging and Age-Related Falls Risk
肌肉疲劳对衰老步态不稳定性和年龄相关跌倒风险的影响
- 批准号:
10677409 - 财政年份:2023
- 资助金额:
$ 3.07万 - 项目类别:
Characterizing gut physiology by age, frailty, and sex: assessing the role of the aging gut in "inflamm-aging"
按年龄、虚弱和性别表征肠道生理学特征:评估衰老肠道在“炎症衰老”中的作用
- 批准号:
497927 - 财政年份:2023
- 资助金额:
$ 3.07万 - 项目类别:
Role of AGE/RAGEsignaling as a driver of pathological aging in the brain
AGE/RAGE信号传导作为大脑病理性衰老驱动因素的作用
- 批准号:
10836835 - 财政年份:2023
- 资助金额:
$ 3.07万 - 项目类别:
Deciphering the role of osteopontin in the aging eye and age-related macular degeneration
破译骨桥蛋白在眼睛老化和年龄相关性黄斑变性中的作用
- 批准号:
10679287 - 财政年份:2023
- 资助金额:
$ 3.07万 - 项目类别:
Elucidation of the protein kinase NLK-mediated aging mechanisms and treatment of age-related diseases
阐明蛋白激酶NLK介导的衰老机制及年龄相关疾病的治疗
- 批准号:
23K06378 - 财政年份:2023
- 资助金额:
$ 3.07万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Underlying mechanisms of age-related changes in ingestive behaviors: From the perspective of the aging brain and deterioration of the gustatory system.
与年龄相关的摄入行为变化的潜在机制:从大脑老化和味觉系统退化的角度来看。
- 批准号:
23K10845 - 财政年份:2023
- 资助金额:
$ 3.07万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Targeting Age-Activated Proinflammatory Chemokine Signaling by CCL2/11 to Enhance Skeletal Muscle Regeneration in Aging
通过 CCL2/11 靶向年龄激活的促炎趋化因子信号传导以增强衰老过程中的骨骼肌再生
- 批准号:
478877 - 财政年份:2023
- 资助金额:
$ 3.07万 - 项目类别:
Operating Grants